Your browser doesn't support javascript.
loading
A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
Bantie, Laychiluh; Tadesse, Solomon; Likisa, Jimma; Yu, Mingfeng; Noll, Benjamin; Heinemann, Gary; Lokman, Noor A; Ricciardelli, Carmela; Oehler, Martin K; Beck, Andrew; Pradhan, Rupal; Milne, Robert; Albrecht, Hugo; Wang, Shudong.
Afiliación
  • Bantie L; Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia.
  • Tadesse S; Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia.
  • Likisa J; Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia.
  • Yu M; Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia.
  • Noll B; Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia.
  • Heinemann G; Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia.
  • Lokman NA; Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, University of Adelaide, Australia.
  • Ricciardelli C; Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, University of Adelaide, Australia.
  • Oehler MK; Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, University of Adelaide, Australia; Department of Gynaecologic Oncology, Royal Adelaide Hospital, Adelaide, Australia.
  • Beck A; Clinical and Health Sciences, University of South Australia, Australia.
  • Pradhan R; Clinical and Health Sciences, University of South Australia, Australia.
  • Milne R; Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia.
  • Albrecht H; Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia.
  • Wang S; Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia. Electronic address: shudong.wang@unisa.edu.au.
Gynecol Oncol ; 159(3): 827-838, 2020 12.
Article en En | MEDLINE | ID: mdl-32958271

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Protocolos de Quimioterapia Combinada Antineoplásica / Quinasa 4 Dependiente de la Ciclina Límite: Animals / Female / Humans Idioma: En Revista: Gynecol Oncol Año: 2020 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Protocolos de Quimioterapia Combinada Antineoplásica / Quinasa 4 Dependiente de la Ciclina Límite: Animals / Female / Humans Idioma: En Revista: Gynecol Oncol Año: 2020 Tipo del documento: Article País de afiliación: Australia